Amneal Pharmaceuticals (NASDAQ:AMRX) Research Coverage Started at Barclays

Barclays initiated coverage on shares of Amneal Pharmaceuticals (NASDAQ:AMRX) in a research report report published on Monday, Marketbeat.com reports. The firm issued an overweight rating and a $15.00 price target on the stock.

A number of other brokerages have also issued reports on AMRX. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, October 8th. Piper Sandler restated an “overweight” rating and set a $13.00 target price (up previously from $11.00) on shares of Amneal Pharmaceuticals in a research report on Friday, October 31st. Finally, JPMorgan Chase & Co. raised their target price on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $13.50.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock opened at $12.21 on Monday. The stock has a fifty day simple moving average of $11.16 and a two-hundred day simple moving average of $9.52. The firm has a market capitalization of $3.84 billion, a PE ratio of 610.81 and a beta of 1.36. Amneal Pharmaceuticals has a 52-week low of $6.68 and a 52-week high of $12.68.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Thursday, October 30th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.12 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 185.60% and a net margin of 0.20%.The business had revenue of $784.51 million for the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. On average, sell-side analysts forecast that Amneal Pharmaceuticals will post 0.53 EPS for the current fiscal year.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, Director Ted C. Nark sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction on Monday, November 17th. The shares were sold at an average price of $11.72, for a total value of $586,000.00. Following the completion of the transaction, the director directly owned 291,029 shares of the company’s stock, valued at $3,410,859.88. This trade represents a 14.66% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Nikita Shah sold 131,856 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $11.92, for a total transaction of $1,571,723.52. Following the completion of the sale, the executive vice president owned 146,403 shares in the company, valued at approximately $1,745,123.76. This trade represents a 47.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 231,856 shares of company stock valued at $2,743,724. 26.56% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Tudor Investment Corp ET AL purchased a new position in Amneal Pharmaceuticals in the third quarter worth about $921,000. CIBC Bancorp USA Inc. bought a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter valued at approximately $161,000. Danske Bank A S bought a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter valued at approximately $1,092,000. Advisory Services Network LLC purchased a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $50,000. Finally, Caxton Associates LLP bought a new position in shares of Amneal Pharmaceuticals during the 3rd quarter valued at approximately $1,351,000. Institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.